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DObjective: Coronary artery bypass grafting (CABG) is the operation most commonly performed by cardiac sur-
geons. There are few contemporary data examining evolving patient characteristics and surgical outcomes of
isolated CABG.We used the Society of Thoracic Surgeons adult cardiac surgery database to characterize trends
in patient characteristics and outcomes after CABG over the past decade.
Methods: From 2000 to 2009, 1,497,254 patients underwent isolated primary CABG at Society of Thoracic Sur-
geons participating institutions. Demographics, operative characteristics, and postoperative outcomes were as-
sessed, and risk-adjusted outcomes were calculated.
Results:Compared with the year 2000, patients undergoing isolated primary CABG in 2009 were more likely to
have diabetes mellitus (33% vs 40%) and hypertension (71% vs 85%). There were clinically insignificant dif-
ferences in age, gender, and body surface area. Between 2000 and 2009, there has been a 6.3% and 19.5% in-
crease in the preoperative use of aspirin and beta-blockers, respectively. Between 2004 and 2009, there was
a 7.8% increase in the use of angiotension-converting enzyme inhibitors preoperatively. Furthermore, between
2005 and 2009 there was a 3.8% increase in the use of statins preoperatively. The median number of distal anas-
tomoses performed was unchanged between 2000 and 2009 (3; interquartile range, 2–4). There was a significant
increase in the use of the internal thoracic artery (88% in 2000 vs 95% in 2009). The predicted mortality rates of
2.3%were consistent between 2000 and 2009. The observed mortality rate over this period declined from 2.4%
in 2000 to 1.9% in 2009 representing a relative risk reduction of 24.4%. The incidence of postoperative stroke
decreased significantly from 1.6% to 1.2%, representing a risk reduction of 26.4%. There was also a 9.2% rel-
ative reduction in the risk of reoperation for bleeding and a 32.9% relative risk reduction in the incidence of
sternal wound infection.
Conclusions: Over the past decade, the risk profile of patients undergoing CABG has changed, with fewer
smokers, more diabetic patients, and better medical therapy characterizing patients referred for surgical coro-
nary revascularization. The left internal thoracic artery is nearly universally used and outcomes have improved
substantially, with a significant decline in postoperative mortality and morbidity. (J Thorac Cardiovasc Surg
2012;143:273-81)Although coronary artery disease (CAD) continues to be the
leading cause of morbidity and mortality in the developed
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The Journal of Thoracic and Cabeen a dramatic reduction in deaths attributable to coronary
heart disease in recent decades.1 Reasons for this decline
include a reduction in risk factors, such as smoking, hyper-
cholesterolemia, and hypertension, and widespread use of
medical therapy, including antihypertensives, beta-
blockers, angiotensin-converting enzyme inhibitors, and
statins.2 In addition, the introduction and widespread use
of surgical and interventional revascularization techniques
have further led to a reduction in mortality attributable to
coronary heart disease.3
Since its introduction in 1962, coronary artery bypass
grafting (CABG) has continued to be the gold standard for
revascularization of CAD, particularly in high-risk patients
with multivessel disease.4 Evidence from multiple studies
suggests thatCABGprolongs survival especially in complex
patients with diabetes,3 those aged 65 years ormore,3,5 those
with left main stem or triple-vessel disease,6 and those with
impaired left ventricular function.6 The Synergy Between
PCI With TAXUS and Cardiac Surgery (SYNTAX) clinical
trial4 revealed that rates of major adverse cardiac orrdiovascular Surgery c Volume 143, Number 2 273
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
IABP ¼ intraaortic balloon pump
ITA ¼ internal thoracic artery
PCI ¼ percutaneous coronary intervention
RRR ¼ relative risk reduction
STS ¼ Society of Thoracic Surgeons
SYNTAX ¼ Synergy Between PCI With TAXUS
and Cardiac Surgery
Acquired Cardiovascular Disease ElBardissi et al
A
C
Dcerebrovascular events at 12 months were significantly
lower in patients with 3-vessel or left main disease who un-
derwent CABG compared with percutaneous coronary in-
tervention (PCI). Despite significant developments in PCI,
CABG remains the most commonly used treatment option
for patients with complex CAD and high-risk patients.7
Despite the known and dramatic effectiveness of CABG,
the use of PCI as a method of revascularization has grown at
a significant rate since its introduction in 19778 and has con-
tributed to a decline in the number of CABGs performed an-
nually.9Given these trends in the incidence of CAD,medical
treatment effectiveness, and alternative interventional CAD
treatment strategies, a number of important clinical ques-
tions arise: (1)Are patients undergoingCABG today charac-
teristically different from patients undergoing CABG in the
past? (2) Have risk-adjusted outcomes improved? (3) Has
the choice of conduits used in CABG evolved?
The purpose of this study is to define how the character-
istics of patients undergoing isolated CABG has changed
during the period of 2000 to 2009, to further characterize
improvements in risk-adjusted clinical outcomes, and to as-
sess how surgical decision-making has changed in the pre-
ceding decade with regard to the number and type of
conduits used.MATERIALS AND METHODS
Study Population
The study population included patients aged 18 years or more who un-
derwent first-time isolated CABG at participating hospitals of the Society
of Thoracic Surgeons (STS) between January 1, 2000, and December 31,
2009. Patients undergoing repeat CABG and patients with missing data
on age, gender, or acuity status were excluded.
Data Elements
Data were collected using 4 versions of the STS data collection as fol-
lows: v2.35 (years 2000–2002), v2.41 (years 2002–2004), v2.52 (years
2004–2007), and v2.61 (years 2008–2009). Note that 2 versions were in
use simultaneously during parts of 2002 and 2004. Definitions for the var-
ious versions of the STS database can be found at http://www.sts.org/
quality-research-patient-safety/national-database/database-managers/adult-
cardiac-surgery-database/d. Definitions were reviewed by the authors to
determine whether study variables had comparable definitions over time.274 The Journal of Thoracic and Cardiovascular SurgVariables that changed substantially were excluded from analysis or ana-
lyzed within shorter time periods during which the definitions were consis-
tent. Variables that were analyzed over shorter time periods are labeled in
the appropriate tables. Variables that had minor definitional changes and
were still used for analysis are shown below with the definitional changes
that occurred:
Preoperative Variable Definitional Changes
 History of cerebrovascular accident: Symptoms persisting for more than
24 hours after initial onset in versions 2.35 and 2.61, and symptoms per-
sisting for more than 72 hours after initial onset in versions 2.41 and 2.52.
 Preoperative arrhythmia: Preoperative arrhythmia present within 2
weeks of the procedure by clinical documentation of any one of the fol-
lowing: atrial fibrillation/flutter requiring treatment, heart block, or
sustained ventricular tachycardia or ventricular fibrillation requiring car-
dioversion or intravenous amiodarone in versions 2.35 and 2.41 versus
history of preoperative arrhythmia (sustained ventricular tachycardia,
ventricular fibrillation, atrial fibrillation, atrial flutter, third-degree heart
block) that has been clinically documented or treated with any of the
following treatment modalities: (1) ablation therapy, (2) automatic im-
plantable cardioverter-defibrillator, (3) pacemaker, (4) pharmacologic
treatment, or (5) electrocardioversion in versions 2.52 and 2.61.
 Procedure status (emergency): The patient’s clinical status includes any
of the following: (a) ischemic dysfunction (any of the following): (1) on-
going ischemia including rest angina despite maximal medical therapy
(medical or intraaortic balloon pump [IABP]), (2) acute evolving myo-
cardial infarctionwithin 24 hours before surgery, or (3) pulmonary edema
requiring intubation. (b) Mechanical dysfunction (either of the follow-
ing): (1) shock with circulatory support or (2) shock without circulatory
support in versions 2.35, 2.41, and 2.52 versus patients requiring emer-
gency operations will have ongoing, refractory (difficult, complicated,
or unmanageable), unrelenting cardiac compromise, with or without he-
modynamic instability, and not responsive to any form of therapy except
cardiac surgery. An emergency operation is one in which there should be
no delay in providing operative intervention in version 2.61.
 Preoperativemedications (aspirin, beta-blockers, steroids):Version2.35did
not indicate time period before surgery, whereas 2.41, 2.52, and 2.61 had
the following time intervals: acetylsalicylic acid (5 days before surgery),
beta-blockers (24 hours before surgery), angiotensin-converting enzyme in-
hibitors (24 hours before surgery), and steroids (24 hours before surgery).
 Preoperative medications (statins): Not included in version 2.35; in-
cluded in versions 2.41, 2.52, and 2.61 with consistent definitions.
Outcome Variable Definitional Changes
 Deep sternal wound infection: Sternal infection/superficial (skin, subcu-
taneous tissue) must have one of the following conditions: (1) wound
opened with excision of tissue (incision and drainage), (2) positive cul-
ture, or (3) treatment with antibiotics in version 2.35 versus deep sternal
infection within 30 days postoperatively, involving muscle, bone, or me-
diastinum requiring operative intervention. Must have all of the follow-
ing conditions: (1) wound opened with excision of tissue (incision and
drainage) or reexploration of mediastinum, (2) positive culture, and
(3) treatment with antibiotics. In versions 2.41, 2.52, and 2.61.
 Stroke: A central neurologic deficit persisting for more than 72 hours
(versions 2.35, 2.41, and 2.52) versus postoperative stroke that did not
resolve in 24 hours (version 2.61).Definition of Study End Points
 Operative mortality defined as death during the same hospitalization as
surgery or after discharge but within 30 days of surgery.ery c February 2012
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D Stroke defined as a central neurologic deficit persisting postoperatively
for more than 24 hours (note that in 2009 definition changed from>24
hours to>72 hours).
The secondary end points of interest included the following:
 Reoperation for bleeding defined as an operative reintervention for
bleeding or tamponade.
 Renal failure defined as an increase of serum creatinine to greater than
2.0 and 2 times most recent preoperative creatinine level or a new re-
quirement for dialysis postoperatively.
 Deep sternal infection, defined as a deep sternal infection involving mus-
cle, bone, or mediastinum with the following requirements: wound
opened with excision of tissue (incision and drainage), positive culture,
or treatment with antibiotics.
 Postoperative length of stay.
 New-onset postoperative atrial fibrillation.FIGURE 1. Enrollment and exclusion criteria. CABG, Coronary artery
bypass grafting; STS, Society of Thoracic Surgeons.Statistical Analysis
Patient characteristics and outcomes were summarized as frequency and
percentage, or as median and interquartile range (25th–75th percentile).
Differences in the prevalence of risk factors in 2000 versus 2009 were as-
sessed with stratified Mantel–Haenszel chi-square tests or Wilcoxon rank-
sum tests, with stratification by STS participant identity. For comparing
outcomes across 2 time points, the percentage relative risk reduction
(RRR) was calculated as 100 3 (P2 – P1)/P1, where P1 and P2 denote the
percentage of patients experiencing the end point in the earlier and later
time periods, respectively. Confidence intervals for the RRR were calcu-
lated by approximating the number of deaths in each time period as a Pois-
son distribution.
To create a patient-level summary measure of case severity, we used
logistic regression modeling to estimate the probability of mortality for
each patient in the study sample. Covariates for predicting mortality in-
cluded age, gender, body surface area, ejection fraction, preoperative dial-
ysis, preoperative atrial fibrillation, cardiogenic shock, immunosuppressive
treatment, PCI less than 6 hours, preoperative intra-aortic balloon pump or
inotrope, peripheral vascular disease, unstable angina (no myocardial in-
farction<7 days), left main disease, cerebrovascular disease (CVD)/cere-
brovascular accident, diabetes, number of disease vessels, myocardial
infarction, operative urgency status, and congestive heart failure/New
York Heart Association class. Covariates were selected on the basis of hav-
ing a previously documented association with mortality,10 a low rate of
missing data, and consistent definitions across the study period. Parameters
of the logistic model were estimated using generalized estimating equa-
tions with an exchangeable correlation structure to account for within-
center clustering. The patient’s estimated probability of death was regarded
as a simple summary measure that combines several individual risk factors
into a single number. Trends in case severity over time were assessed by
calculating the average estimated probability of death among all patients
in the same calendar year to obtain the year-specific predicted mortality
prevalence rate. Analogous models and measures were also created for
the 6 nonfatal end points.
Trends in short-term mortality and morbidity outcomes over time were
assessed by calculating unadjusted and risk-adjusted prevalence rates for
each study end point by calendar year. The unadjusted prevalence rate
was defined as the proportion of patients in a given calendar year who
had the end point of interest. The risk-adjusted prevalence rate for a given
end point and calendar year was calculated by dividing the year-specific
unadjusted prevalence rate of the end point (defined above) by the year-
specific predicted prevalence rate of the end point (defined in the previous
paragraph) and then multiplying by the overall proportion of patients who
had the end point during the entire study period. The calculation of risk-
adjusted RRRs and associated confidence intervals was similar to theThe Journal of Thoracic and Caunadjusted versions described above. Given the large sample size, P values
will not be reported because practically every difference is statistically sig-
nificant, however, not necessarily clinically significant.
STS data were highly complete with most study variables missing less
than 1% in each calendar year. Missing data rates were highest in 2000 and
generally lower in each successive calendar year. Covariates with the most
missing data had the following missing data rates for calendar years 2000
and 2009: ejection fraction (7.8%, 3.5%), use of ITA (4.6%, 0.0%), and
off-pump procedure (3.3%, 0.0%). Remaining variables had less than
3% missing in each calendar year or are explicitly stated in data tables.
For each variable, summary measures are based on the subset of patients
without missing data.RESULTS
Patient Population
From 2000 to 2009, 2,473,313 patients underwent car-
diac surgery at 1073 institutions participating in the STS
Adult Cardiac Surgery Database (Figure 1). After exclusion
of patients undergoing non-CABG procedures (28%), pa-
tients undergoing concomitant operations (11.7%), patients
undergoing reoperative CABGs (4.6%), and patients with
missing age or gender data (0.1%), 1,497,254 patients
make up the study base for this analysis.rdiovascular Surgery c Volume 143, Number 2 275
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DCharacteristics of Patients Undergoing Coronary
Artery Bypass Grafting
As shown in Table 1, between 2000 and 2009 there has
been a modest increase in diabetes mellitus and a significant
increase in hypertension. There were minor differences in
age and body surface area over time. Use of statins, aspirin,
beta-blockers, and angiotensin-converting enzyme inhibi-
tors increased by 3.8%, 6.3%, 19.5%, and 7.8%, over their
respective periods of data collection (see Table 1 footnote).
Further, there was a 37% increase the number of patients
who underwent PCI with or without stenting before under-
going CABG (19% vs 26%).
Table 2 highlights the hemodynamic and catheterization
characteristics of patients undergoing primary CABG. The
percent of patients with left main disease increased from
22.6% in 2000 to 31.6% in 2009. The median ejection frac-
tion increased from 50% in 2000 to 55% in 2009, whereas
the incidence of 3-vessel disease increased marginally.
Operative Characteristics
As shown in Table 3, there has been an increase in the use
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CVD without previous CVA
Preoperative arrhythmia
Previous interventions
Preoperative PCI (with or without stenting)<6 h
Any prior PCI (with or without stenting)
Previous valve surgery






In year 2000, ACE inhibitor and statin missing data exceeded 3%. ACE, Angiotensin-conve
obstructive pulmonary disease; CVA, cerebrovascular accident; NYHA, New York Heart A
yData are from 2005, not 2000.
276 The Journal of Thoracic and Cardiovascular Surgrevascularization, increasing from 87.7% in 2000 to
94.7% in 2009. Use of the isolated right ITA for primary
CABGs remained constant at less than 0.6% throughout
the study, whereas use of bilateral ITAs increased slightly
from 3.5% in 1999 to 4.1% in 2009. The radial artery
also had varying rates of adoption since 2000 when it was
used in 10.8% of all primary CABGs. Use of the radial ar-
tery peaked at 12.3% in 2002 and subsequently declined to
5.5% in 2009.
As a proportion of total procedures (Table 3), elective
CABG is being performed less in 2009 than in 2000
(57.6% elective in 2000 vs 41.3% elective in 2009). There
was a concomitant increase in the number of urgent cases
(38.0% vs 54.1%), although emergency and emergency-
salvage cases remained constant throughout the study. Fi-
nally, although the timing of IABP implantation seems to
have changed over time (more patients with IABP preoper-
atively and fewer with IABP intraoperatively and postoper-
atively), the overall proportion of patients receiving an
IABP has remained constant at approximately 10%
(Table 3). Perfusion and crossclamp times remained rela-
tively constant in this study, although the proportion ofgrafting between 2000 and 2009
2000 2009
65 (57–73) 65 (57–73)
70.6% 72.9%
92.0% 85.0%
84 (73–95) 86 (75–100)





















rting enzyme; BSA, body surface area; CHF, congestive heart failure; COPD, chronic
ssociation; PCI, percutaneous coronary intervention. *Data are from 2004, not 2000.
ery c February 2012
TABLE 2. Coronary lesions and ejection fraction
Hemodynamics 2000 2009
Demographics
Left main disease>50% 22.6% 31.6%




Ejection fraction 50 (40–60) 55 (45–60)
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Dcases performed off-pump increased from 14.5% in 2000 to
21.1% in 2009.FIGURE 2. Primary outcomes: mortality (A) and stroke (B). Note that
stroke definition changed from permanent central nervous system deficit
persisting for more than 24 hours during 2000–2008 to a central nervous
system deficit persisting for more than 72 hours in 2009. CABG, Coronary
artery bypass grafting.Outcomes in Total Cohort
As shown in Figure 2, A and Table 4, the change in patient
demographic and preoperative risk resulted in a relatively
constant predicted mortality rate throughout the duration
of this study. There was a 24.4% and 26.4% reduction in
the unadjusted observed operative mortality (2.4% vs
1.9%) and stroke rates (1.6% vs 1.2%), respectively, dur-
ing the course of the study period (Table 4). There was
also a 9.2% RRR in the incidence of reoperation for bleed-
ing (2.5% vs 2.2%, Table 4) and a 32.9% relative reduction
in the incidence of sternal wound infection (0.55% vs
0.37%, Table 4). There was a 5.5% relative increase in
the incidence of new-onset renal failure between 2000
and 2009 and a 6.5% relative increase in the incidence of
new postoperative atrial fibrillation (Table 4). Median
length of stay was 5 days (interquartile range, 4–7) and
did not change throughout the course of the study.TABLE 3. Operative characteristics
Operative characteristics 2000 2009
Use of internal thoracic 87.7% 94.7%





Emergency salvage 0.2% 0.2%
Perfusion time 92 (72–116) 89 (69–113)
Crossclamp time 61 (45–81) 62 (46–82)






IABP missing timing 0.2% 0.0%
IABP preoperative 6.7% 8.1%
IABP intraoperative 1.6% 1.5%
IABP postoperative 0.4% 0.3%
IABP, Intraaortic balloon pump.
The Journal of Thoracic and CaOutcomes in Elective/Urgent Cohort
Patients undergoing emergency and emergency-salvage
operations were removed from the total cohort to evaluate
the outcomes after elective CABG. As shown in Table 4,
there was a 26.5% and 27.4% relative reduction in the ob-
served operative mortality (2.1% vs 1.6%) and stroke rates
(1.6% vs 1.1%) in the combined elective/urgent popula-
tion, respectively. Similar to findings in the total cohort,
there was also a 10.1% relative reduction in the incidence
of reoperation for bleeding (2.4% vs 2.1%) and a 32.7%
relative reduction in the incidence of sternal wound infec-
tion (0.54% vs 0.36%, Table 4). There was a 26.5% reduc-
tion in the incidence of new-onset renal failure in the
combined elective/urgent population. Similar to the find-
ings in the total cohort, there was a 6.7% relative increase
in the incidence of new postoperative atrial fibrillation
(19.7% vs 21.0%).DISCUSSION
By using the STS Adult Cardiac Surgery Database, this
retrospective 10-year study consisting of 1.4 million pa-
tients identifies a number of important trends in patient
characteristics, operative approaches, and outcomes among
patients undergoing CABG. Although patient risk profiles
have evolved significantly, the overall predicted risk of mor-
tality remained constant. Despite this overall unchangedrdiovascular Surgery c Volume 143, Number 2 277
TABLE 4. Outcomes in total cohort and nonemergency/salvage subcohort
Total cohort Nonemergency/salvage sub-cohort
2000 2009 P value Relative risk change 2000 2009 P value Relative risk change
Mortality
Observed 2.4% 1.9% <.0001 24.4% (28.7% to20.1%) 2.1% 1.6% <.0001 26.5% (31.2% to21.8%)
Predicted 2.3% 2.3% 1.9% 1.8%
Adjusted 2.3% 1.7% <.0001 22.8% (27.3% to18.3%) 2.0% 1.5% <.0001 22.6% (27.6% to17.7%)
Stroke
Observed 1.6% 1.2% <.0001 26.4% (31.6% to21.1%) 1.6% 1.1% <.0001 27.4% (32.9% to21.9%)
Predicted 1.3% 1.3% 1.3% 1.3%
Adjusted 1.6% 1.2% <.0001 26.4% (31.6% to21.2%) 1.6% 1.2% <.0001 26.9% (32.4% to21.5%)
Renal failure
Observed 3.5% 3.6% .005 5.5% (1.6%–9.3%) 2.1% 1.6% <.0001 26.5% (31.2% to21.8%)
Predicted 3.8% 4.0% 1.9% 1.8%
Adjusted 3.2% 3.2% .956 0.1% (4.1% to 3.9%) 2.0% 1.5% <.0001 22.6% (27.6% to17.7%)
Reoperation for bleed
Observed 2.5% 2.2% <.0001 9.2% (13.6% to4.7%) 2.4% 2.1% <.0001 10.1% (14.8% to5.5%)
Predicted 2.5% 2.4% 2.4% 2.3%
Adjusted 2.4% 2.2% .002 7.1% (11.6% to2.5%) 2.3% 2.1% <.0001 7.3% (12.1% to2.6%)
Deep sternal wound infection
Observed 0.55% 0.37% <.0001 32.9% (41.8% to23.9%) 0.54% 0.36% <.0001 32.7% (42.0% to23.5%)
Predicted 0.41% 0.43% 0.40% 0.42%
Adjusted 0.59% 0.37% <.0001 37.3% (45.8% to28.7%) 0.57% 0.36% <.0001 36.9% (45.8% to28.0%)
Atrial fibrillation
Observed 19.8% 21.1% <.0001 6.4% (4.9%–7.8%) 19.7% 21.0% <.0001 6.7% (5.2%–8.2%)
Predicted 20.3% 21.2% 20.2% 21.0%
Adjusted 20.0% 20.5% .004 2.2% (0.7%–3.6%) 19.9% 20.4% .001 2.5% (1.0%–4.0%)
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Drisk, outcomes have substantially improved, with mortality
and stroke rates decreasing by 24.4% and 26.4%, respec-
tively. In addition, there have been significant reductions
in the risks of reoperation for bleeding and deep sternal
wound infections in the total cohort and non-emergency
subcohort, as well as a reduction in postoperative renal fail-
ure only in non-emergency patients. Of note, patients under-
going CABG in the current era are currently receiving
superior revascularization conduits and configurations,11,12
including more frequent use of the ITA (94.7% vs 87.7%)
and nearly all patients receiving at least 1 arterial bypass
graft. Although this study is limited in that it does not
contain long-term outcomes, the conduits that are currently
used are likely to result in superior patency, freedom from
angina, and long-term survival compared with patients un-
dergoing CABG 10 years ago.13-16
Many studies compare outcomes between CABG and
PCI over a medium to long-term time horizon,17-21 failing
to take into account the incremental improvement in
outcomes that occurs as a result of improvements in the
inherent safety of surgery. This substantial body of
literature comparing outcomes after CABG versus PCI
may be somewhat dated, and conclusions from those
studies may not be valid in the current era because of the
progressive improvement in quality and outcomes of
CABG demonstrated here. This study illustrates that there
has been a steady and dramatic improvement in outcomes278 The Journal of Thoracic and Cardiovascular Surgover the past decade that are not due to decreasing patient
risk, but rather to improvements in the performance and
safety of the surgical procedure and preoperative and
postoperative medical treatment. There are a plethora of
data indicating that surgery is superior in terms of target
vessel revascularization18 and freedom from revasculariza-
tion,22 especially in patients with complex lesions and mul-
tivessel disease.18 Thus, in addition to gaining the long-term
revascularization and survival benefits after surgery, pa-
tients undergoing CABG in the current era also benefit
from improved decreased short-term complications, such
as operative mortality, stroke, sternal wound infections, re-
operations for bleeding, and renal failure requiring dialysis,
a phenomenon that is just now being identified in the most
recent studies comparing CABG and PCI.22
One of the major findings of this study is the use of supe-
rior conduits (particularly the left ITA) during the time
period analyzed. Although a major factor in the improve-
ment in compliance is likely due to research indicating im-
proved patient survival and patency,11,13-15 the STS
database has been instrumental in achieving this target by
providing surgeons with regular reports of their
performance relative to national benchmarks, ultimately
facilitating improvement in the quality of care delivered.
Further, use of the ITA and mortality are both quality
indicators in the STS CABG quality measurement
initiative.23,24 Additional factors that may be contributingery c February 2012
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medical optimization (as demonstrated by improved
compliance with medications such as aspirin, statins,
beta-blockers, and angiotensin-converting enzyme inhibi-
tors), improved postoperative critical care, and improved
performance in the operating room. Although it is beyond
the scope of this article to identify the impact of these fac-
tors, previous literature has documented significant im-
provements in each of these areas in the past decade.
The change in the demographics, hemodynamics, and an-
atomic characteristics reflect the prevalence of PCI and the
improved effectiveness of preventative medicine and phar-
macologic therapy. During the past decade, there has been
a 9.0% absolute increase in the number of patients present-
ing with more than 50% occlusion of the left main coronary
artery. Furthermore, patients in the current era are present-
ing with a high frequency of comorbid conditions likely due
to literature that has indicated significant short and long-
term benefit in patients with a high atherosclerotic burden
and multivessel disease25,26 in CABG versus PCI.Limitations
The strengths of this study are in its large sample size re-
flecting a large majority of CABGs that have been per-
formed in the United States from 2000 to 2009. As such,
these results are robust and generalizable to the entire pop-
ulation of patients undergoing CABG. One key limitation of
the STS Adult Cardiac Surgery Database is that it is limited
to short-term outcomes. Although there is evidence to sug-
gest that long-term survival may be improved in the cohort
of patients currently undergoing CABG given the superior-
ity of conduits, there was no effort to assess these outcomes.CONCLUSIONS
Over the past decade there have been significant reduc-
tions in the incidences of mortality, stroke, reoperations
for bleeding, sternal wound infections, and new-onset renal
failure in non-emergency patients. These outcomes seem to
reflect improvements in the surgical procedure, rather than
a change in the operative risk of patients currently undergo-
ing CABG. Elective CABG is now performed in North
America with a mortality rate of 1.6% and a stroke rate
of 1.1%. Although these improvements in outcomes are
significant, future challenges for cardiac surgery as a spe-
cialty are to focus on continued reduction of mortality of
CABG, stroke, and renal failure. These outcomes should
serve as benchmarks for competing therapies for multives-
sel cardiovascular disease.References
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Dr T. Bruce Ferguson (Greenville, NC). This nice analysis of
major patient risk factor observational processes and outcomes
compared between 2000 and 2009 (>1.4 million patients) is an ex-
cellent update. They did a nice job of handling different versions of
the STS database data in their trends over time analysis. The study
clearly documented continued improvement in CABG outcomes,
particularly in the CABG PCI era of the last decade.
I have 2 questions for the authors. The first is, you appropriately
attribute improvement to better perioperative management overall,
but 25% of the patients in 2009 had prior PCI and 32% had left
main disease, and the number of distal anastomoses increased
from 2000 to 2009. These are clearly more technically difficult op-
erations. Given your study and the recent JAMA report on the over-
all decline in CABG volumes during this same time frame,
although the number of CABG sites has increased, do you foresee
a reversal in this trend as sites perform fewer and fewer CABG pro-
cedures, and if so, what might be done about this at the local level?
The second question is that you discussed CABG versus PCI
outcomes in your article and the difference in the SYNTAX mor-
tality outcomes. If you substitute the SYNTAX PCI arm data with
the fractional flow reserve–guided PCI data from FFR versus An-
giography for Guiding PCI in Patients with Multivessel Coronary
Artery Disease (FAME), the mortality benefit from CABG disap-
pears. While this is being tested directly in the National Heart,
Lung, and Blood Institute ischemia trial, which is just getting un-
der way, what do you recommend as options to further improve
CABG outcomes in the future to keep up with our interventional
colleagues?
Dr ElBardissi. With regard to your first question, a number of
studies recently have shown that although there was a significant
decline in number of CABGs performed immediately after PCI
was adopted and certainly through the 1980s and 1990s, there
has certainly been a more recent decrease in the decline in
CABG volume. Furthermore, we believe that with studies like
these showing excellent outcomes after CABG, we continue to ex-
pect, at the very least, the decline in the number of CABGs to tem-
per even further.
Dr Ferguson. Sorry. My question was the decline in the im-
provement in outcomes from CABG, not the decline in the number
of CABGs that are done.
Dr ElBardissi. That is a very different question. It certainly is
possible that average institutional volumes will decline as a result
of the combination of decreasing global CABG volumes and an in-
crease in the number of hospitals performing CABG, and lower
volumes could reverse the trend toward improved outcomes. The
volume–outcome relationship for CABG is not as strong as for
some other cardiac operations. It should be noted that these data280 The Journal of Thoracic and Cardiovascular Surginclude only immediate postoperative outcomes, thus making it
hard to infer potential differences in long-term outcomes, includ-
ing long-term survival and revascularization.
I think your second question referred to CABG versus PCI out-
comes and recommending additional interventions or therapies
that would potentially improve the performance of CABG in rela-
tive to PCI. This study clearly illustrates we are performing CABG
on a very different cohort of patients and patients compared with
10 years ago.
It is essential that we continue to focus on reducing not only
mortality but also 2 keymorbidities: stroke and renal failure. There
remains room for improvement here.
Dr Paul Kurlansky (Miami, Fla). A very interesting study. It
parallels some work that was done by Dr Ferguson and colleagues
with regard to the STS database in the 1990s, who showed an in-
creasing risk and declining mortality for CABG surgery, and sim-
ilar findings have been shown in the New York State database over
time with increasing risk and declining mortality. I was wondering
if you would care to comment on the potential impact of large reg-
istries, which make us all aware of our results, on the actual out-
comes that we have been observing?
Dr ElBardissi. This is by far the largest cohort of patients we
have reviewed (1.4 million patients over the past decade), and
we have done a rigorous analysis to not only adjust for preopera-
tive risk but also ensure that the variables we are looking at are
consistent over time. I think all of us in this room recognize that
the STS database is one of the most valuable assets of the specialty
of cardiac surgery.
The major implication of this study is that we are in fact oper-
ating on amore complex cohort of patients and doing a better job at
getting them through the immediate postoperative phase with less
complications and particularly less mortality and less stroke than
they were not too long ago, 10 years ago.
The STS database was set up for quality improvement, and the
results of this study suggest that it has succeeded in that role. By
providing cardiac surgeons with regular reports that include risk-
adjusted outcomes for CABG and other cardiac operations along
with national and regional benchmarks, the STS database has cat-
alyzed improvement in both process and outcomes. The process of
measuring and reporting outcomes has been a powerful stimulus
for practice improvement.
Dr James Tatoulis (Melbourne, Australia). I noticed that less
than 5% of patients were having bilateral ITAs despite the cohort
having a median age of 65 years. Could you comment on how this
has changed in the last 10 years, particularly now the population is
aging and patients live longer, and whether you can use this type of
study to perhaps stimulate some progress in that area?
Dr ElBardissi. Bilateral ITAs at the beginning of our study
were 3.5%, and it just increased slightly to 4.1% at the end of
the study; an increase in the use of bilateral ITAs but certainly
not a large increase. Certainly increased focus on the rate of bilat-
eral ITA grafting might lead to increased adoption of this strategy.
Dr Ottavio Alfieri (Milan, Italy). What is your personal inter-
pretation of the improvements? If you could identify just a single
factor affecting this improvement, what do you think it is?
Dr ElBardissi. We have seen improvements on many fronts.
We have seen improvements on process-oriented fronts, surgical
decision-making fronts, such as use of the ITA, and then weery c February 2012
ElBardissi et al Acquired Cardiovascular Diseasehave also seen improvements on the outcome fronts, mortality,
stroke rate, and so forth. The process-orientated fronts and surgical
decision-making fronts tend to reflect, again, the rigorous clinical
studies that are ongoing in the field of cardiac surgery that dictate
to us as cardiac surgeons what the optimal revascularization con-
figuration and strategies are going forward in any particular group
of patients.
The changes in outcomes we have seen, again, adjusting for
patient risk and still seeing a significant decline in mortality
and stroke rate, reflect a number of things. Number one, theyThe Journal of Thoracic and Careflect more optimal medical management when patients come
into surgery. Something that shouldn’t be lost is that this is
not just better care being received in the operating room, this
is probably better perioperative surgical care, preoperative, oper-
ative, and intensive care unit level care and floor level care. So I
think there are a number of things are going on here. It is diffi-
cult to know from our study exactly what is contributing to the
improved outcomes we have seen over the past decade, but cer-
tainly better intraoperative decision-making and better perioper-
ative surgical care.rdiovascular Surgery c Volume 143, Number 2 281
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